Allogeneic serum responses against CLL-associated antigens
| Serum . | Clone . | CLL . | Lymphoma . | Healthy . | Detection as antigen in other studies . |
|---|---|---|---|---|---|
| Only CLL | KW-1 | 2 of 12 | 0 of 5 | 0 of 12 | |
| KW-3 | 2 of 16 | 0 of 5 | 0 of 12 | ||
| KW-4 | 3 of 12 | 0 of 5 | 0 of 12 | ||
| KW-2 | 3 of 12 | 0 of 5 | 0 of 12 | AF286340 | |
| KW-8 | 4 of 23 | n.d. | 0 of 12 | 16 | |
| KW-12 | 2 of 16 | 0 of 5 | 0 of 12 | 21 | |
| CLL + lymphoma | KW-6 | 2 of 12 | 1 of 5 | 0 of 12 | |
| KW-10 | 2 of 24 | 2 of 5 | 0 of 12 | ||
| KW-7 | 3 of 23 | 1 of 5 | 0 of 12 | 44 | |
| KW-11 | 4 of 23 | 3 of 5 | 0 of 12 | 17.25 | |
| KW-14 | 3 of 16 | 1 of 5 | 0 of 12 | 17 | |
| CLL + lymphoma + healthy donors | KW-5 | 20 of 30 | 2 of 5 | 2 of 12 | |
| KW-9 | 14 of 15 | 5 of 5 | 10 of 12 | ||
| KW-13 | 7 of 16 | 2 of 5 | 3 of 12 |
| Serum . | Clone . | CLL . | Lymphoma . | Healthy . | Detection as antigen in other studies . |
|---|---|---|---|---|---|
| Only CLL | KW-1 | 2 of 12 | 0 of 5 | 0 of 12 | |
| KW-3 | 2 of 16 | 0 of 5 | 0 of 12 | ||
| KW-4 | 3 of 12 | 0 of 5 | 0 of 12 | ||
| KW-2 | 3 of 12 | 0 of 5 | 0 of 12 | AF286340 | |
| KW-8 | 4 of 23 | n.d. | 0 of 12 | 16 | |
| KW-12 | 2 of 16 | 0 of 5 | 0 of 12 | 21 | |
| CLL + lymphoma | KW-6 | 2 of 12 | 1 of 5 | 0 of 12 | |
| KW-10 | 2 of 24 | 2 of 5 | 0 of 12 | ||
| KW-7 | 3 of 23 | 1 of 5 | 0 of 12 | 44 | |
| KW-11 | 4 of 23 | 3 of 5 | 0 of 12 | 17.25 | |
| KW-14 | 3 of 16 | 1 of 5 | 0 of 12 | 17 | |
| CLL + lymphoma + healthy donors | KW-5 | 20 of 30 | 2 of 5 | 2 of 12 | |
| KW-9 | 14 of 15 | 5 of 5 | 10 of 12 | ||
| KW-13 | 7 of 16 | 2 of 5 | 3 of 12 |
Phage plaque assay using multiple sera was performed. Screening results of multiple sera from patients with CLL, other lymphoma, and healthy donors for presence of antibodies against identified clones are shown. Previous detection of CLL-associated antigens in other studies is indicated.